CUVL

Clinuvel Pharmaceuticals Limited

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$5.05

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %36.3 / %30

Non-compliant revenue / Total income %9.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Website

Analysis (Turkish): CUVL Hissesi Caiz mi, Helal mi? Clinuvel Pharmaceuticals Limited Katılım Analizi